Back to funds
View filing
Squadron Capital Management LLC
hedge fundUpdated 27 days agoManaged by Squadron Capital Management Llc • Latest filing Q2 2026
Portfolio value
$322.2M
Q2 2026
Filings
3
Quarterly 13F history
Top-10 concentration
90.6%
Weight of largest holdings
Annualized return
—
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 3 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q4 2025 | $236M |
| Q1 2026 | $272.9M |
| Q2 2026 | $322.2M |
Top holdings
43 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | R RLMD RELMADA THERAPEUTICS INC | $50.9M | 7.35M | 15.78% | — |
| 2 | B BEPC C4 THERAPEUTICS INC | $33.6M | 7.20M | 10.43% | — |
| 3 | C COGT COGENT BIOSCIENCES INC | $33.5M | 865.0K | 10.39% | — |
| 4 | K KOD KODIAK SCIENCES INC | $19.5M | 500.0K | 6.05% | — |
| 5 | R RLAY RELAY THERAPEUTICS INC | $18.1M | 970.0K | 5.63% | — |
| 6 | ? N/A ZENTALIS PHARMACEUTICALS INC | $17.9M | 3.70M | 5.57% | — |
| 7 | E EWTX EDGEWISE THERAPEUTICS INC | $11.8M | 290.0K | 3.66% | — |
| 8 | M MAZE MAZE THERAPEUTICS INC | $10M | 335.0K | 3.10% | — |
| 9 | I IVEVF INVENTIVA SA | $9.2M | 2.44M | 2.86% | — |
| 10 | A ANL ADLAI NORTYE LTD | $8.8M | 764.9K | 2.73% | — |
| 11 | E ELVN ENLIVEN THERAPEUTICS INC | $8.1M | 160.0K | 2.52% | — |
| 12 | A AVBP ARRIVENT BIOPHARMA INC | $6.4M | 183.0K | 1.97% | — |
| 13 | ? N/A PALISADE BIO INC | $6.3M | 3.00M | 1.95% | — |
| 14 | ? N/A BIOAGE LABS INC | $6.1M | 250.0K | 1.90% | — |
| 15 | I IKT INHIBIKASE THERAPEUTICS INC | $6.1M | 3.00M | 1.89% | — |
| 16 | A ADAG ADAGENE INC | $5.3M | 1.25M | 1.63% | — |
| 17 | F FBRX FORTE BIOSCIENCES INC | $4.8M | 225.0K | 1.48% | — |
| 18 | R RZLT REZOLUTE INC | $4.7M | 900.0K | 1.45% | — |
| 19 | I IFRX INFLARX NV | $4.5M | 2.00M | 1.39% | — |
| 20 | A ASH ASSEMBLY BIOSCIENCES INC | $4.4M | 160.0K | 1.36% | — |